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Background
The MPER of HIV-1 gp140 contains the epitopes for the
cross-clade neutralising antibodies, 4E10 and 2F5. How-
ever, there is evidence that the 4E10 epitope is located in
other regions apart from the MPER and that expression
levels of recombinant gp140s from stable CHO lines are
lower if the 4E10 epitope is included.
Methods
To investigate the contribution of the MPER to the anti-
genicity and immunogenicity of HIV-1 envelope glyco-
proteins, three lines of investigation were followed: 1 -
immunisation of rabbits with C-clade gp140s with/with-
out MPER; 2 - Biacore studies of antibody and sCD4 bind-
ing of gp140s with/without MPER; 3 - Neutralisation of
pseudoviruses with/without MPER by MAb 4E10.
Results
The results indicate that the possession of the MPER 4E10
epitope by pseudoviruses is sufficient for neutralisation by
the 4E10 MAb. However, the addition of the 4E10 epitope
reduced expression of gp140 from stable CHO lines by
over 50% and has a marked effect on the binding of the
b12 MAb, which recognises the CD4 binding site, and
sCD4. Finally, mean end-point antibody titres from
immunised rabbits were lower in animals immunised
with C-clade gp140 which contains the 4E10 epitope. An
analysis of breadth and potency of neutralising responses
raised in these animals is underway.
Conclusion
The data suggests that the addition of the 4E10 epitope to
HIV-1 gp140 has profound effects on the structure of
gp140, which affects the expression levels, antigenicity
and immunogenicity of these glycoproteins.
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